| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Biolase (NASDAQ:BIOL) reported its Q4 earnings results on Thursday, March 21, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
Biolase beat estimated earnings by 31.0%, reporting an EPS of $-1.76 versus an estimate of $-2.55.
Revenue was down $561 thousand from the same period last year.
Last quarter the company missed on EPS by $2.04 which was followed by a 20.0% drop in the share price the next day.
Here's a look at Biolase's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -1.85 | -5.33 | -20 | -64 |
| EPS Actual | -3.89 | -4.24 | -18 | -128 |
| Revenue Estimate | 13.96M | 15.36M | 10.18M | 14.07M |
| Revenue Actual | 10.92M | 14.29M | 10.47M | 14.05M |
To track all earnings releases for Biolase visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: BIOL
